In the IL3RA-positive HDLM-2 subcutaneous Hodgkin lymphoma model, IL3RA-ADC treatment also resulted in significant antitumor efficacy with most animals being tumor-free at the end of the study. The gene discussed is IL3RA; the disease is Hodgkins lymphoma.